Abstract #5243
Quantitative validation of 7T MRSI in gliomas by targeted mass spectrometry
Sagar Acharya1,2,3, Cornelius Cadrien1,2, Sara Huskic1,2, Philipp Lazen1, Ahmet Azgin1, Christina Brenner4, Julia Furtner5, Barbara Kiesel2, Lisa Koerner2, Matthias Preusser6, Thomas Roetzer-Pejrimovsky7, Gunda Köllensperger4, Siegfried Trattnig1,8,9, Wolfgang Bogner1, Georg Widhalm2, Karl Rössler2, and Gilbert Hangel2,3,10
1High-field MR Center, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria, Vienna, Austria, 2Department of Neurosurgery, Medical University of Vienna, Vienna, Austria, Vienna, Austria, 3Christian Doppler Laboratory for MR Imaging Biomarkers, Vienna, Austria, Vienna, Austria, 4Institute for Analytical Chemistry, University of Vienna, Vienna, Austria, Vienna, Austria, 5Division of Neuroradiology and Musculoskeletal Radiology, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria, Vienna, Austria, 6Division of Oncology, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria, Vienna, Austria, 7Division of Neuropathology and Neurochemistry, Department of Neurology, Medical University of Vienna, Vienna, Austria, Vienna, Austria, 8Christian Doppler Laboratory for Clinical Molecular MR Imaging, Vienna, Vienna, Austria, 9Institute for Clinical Molecular MRI, Karl Landsteiner Society, St. Pölten, Austria, St. Polten, Austria, 10Functional Imaging Laboratory, Department of Imaging Neuroscience, UCL Queen Square Institute of Neurology, University College London, UK, London, United Kingdom
Synopsis
Keywords: Spectroscopy, Spectroscopy, Glioma
Motivation: Accurate molecular and pathological diagnoses rely on fresh tissue samples, making it essential to precisely sample and preserve the tumor to maintain its integrity.
MRSI accurately identifies tumor hotspots and can be used for obtaining high quality samples.
Goal(s): To validate MRSI maps using mass spectrometry as a gold standard.
Approach: We processed 7T MRSI metabolic ratio maps to identify tumor hotspots, which we subsequently compared with their quantitatively analysed metabolic profiles.
Results: We obtained high quality samples based on our 7T MRSI maps. The MRSI vs MS profiles show limited correlations, however, with a scope to improve.
Impact: Using 7T MRSI maps to sample metabolic hotspots allowed us to compare MRSI findings with histological and quantitative features. We demonstrated that combining MRSI and MS offers a more comprehensive metabolic profile of gliomas with room for improvement.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Click here for more information on becoming a member.
